Five things for pharma marketers to know: Thursday, October 19, 2017
Novaris was the first company to begin marketing a CAR-T therapy. Photo Credit: Brent Stirton for Novartis/Verbatim Agency
1. The FDA approved the second CAR-T therapy, Kite Pharma's Yescarta, as a treatment for certain patients with an aggressive forms of a blood cancer. The author of one of the studies called the results “pretty remarkable.” Still, there are concerns about how these therapies will be priced. (NYT)
2. Omnicom Group reported that revenue in its specialty communications business rose 5% in the third quarter of 2017. It cited the performance of its U.S. healthcare agencies as a driver of revenue growth.
3. Hearst said it will acquire Rodale, the publisher of Women's Health, Men's Health, and Prevention, in a bid to boost its presence in the health and wellness market. (WSJ)
4. An FDA advisory committee voted 16-0 in favor of the agency approving Novo Nordisk's semaglutide, an experimental once-weekly injectable type 2 diabetes treatment. If approved, the drug will likely compete with Eli Lilly's Trulicity. (Medscape)
5. Another FDA advisory committee recommended that the regulator approve GlaxoSmithKline's new shingles vaccine, Shingrix. It will likely compete with Merck's shingles vaccine Zostavax. (Stat)